Tian BP, et al. - Researchers analyzed 7 randomized controlled trials including overall 2,321 subjects, reporting the therapeutic efficacy and safety of benralizumab [a humanized monoclonal antibody that targets the α chain of the IL-5 receptor (IL-5Rα)] in patients with eosinophilic asthma. These studies were identified from PubMed, Embase, and the Cochrane Library and data were pooled. Findings showed that, benralizumab vs placebo resulted in significant reductions in the exacerbations, with no increased incidence of adverse events. Benralizumab was well tolerated. Overall, benralizumab was proved to be efficacious and safe for asthma patients with severe or uncontrolled symptoms and elevated eosinophils. Benralizumab was suggested as an ideal option to treat asthma in this patient population.